camptothecin has been researched along with Breast Cancer in 389 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (11.05) | 18.2507 |
| 2000's | 116 (29.82) | 29.6817 |
| 2010's | 120 (30.85) | 24.3611 |
| 2020's | 110 (28.28) | 2.80 |
| Authors | Studies |
|---|---|
| Bisagni, E; Croisy, A; Janin, YL; Riou, JF | 1 |
| Cao, Z; Giovanella, B; Harris, N; Kozielski, A; Stehlin, JS; Vardeman, D | 1 |
| Furbacher, TR; Gunatilaka, AA | 1 |
| Bandrés, E; Chozas, H; Cordeu, L; Cubedo, E; Echeverría, M; Font, M; García-Foncillas, J; Mendivil, B; Palop, JA; Rebollo, A; Sáenz, X; Sanmartin, C; Victoria Domínguez, M | 1 |
| Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
| Bailly, C; Baldeyrou, B; Beauchard, A; Besson, T; Chérouvrier, JR; Domon, L; Jaunet, A; Lansiaux, A; Murillo, L; Picot, L; Thiéry, V | 1 |
| M Padrón, J; Machin, RP; Nicotra, VE; Oberti, JC; Veleiro, AS | 1 |
| Chavez, KJ; Feng, X; Flanders, JA; Rodriguez, E; Schroeder, FC | 1 |
| Guendisch, D; Kondratyuk, TP; Marler, L; Park, EJ; Pezzuto, JM; Shen, L; Sun, D; Wright, AD | 1 |
| Dang, TT; Dao, TT; Le, TV; Nguyen, QT; Oh, WK; Pham, TH; Thuong, PT | 1 |
| Chen, YJ; Kamath, A; Ojima, I; Seitz, JD; Vineberg, JG; Zuniga, ES | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Magar, TB; Na, Y; Park, S; Shrestha, A | 1 |
| Islam, MS; Kadi, AA; Kwon, Y; Park, S; Rahman, AF; Song, C | 1 |
| He, D; Rakotondraibe, LH; Slebodnick, C | 1 |
| Agama, K; An, LK; Chen, JW; Hu, DX; Pommier, Y; Tang, WL; Yang, H; Yu, Q; Zhang, Y | 1 |
| Hwang, SY; Jeon, YH; Jeong, TC; Jo, H; Kadayat, TM; Katila, P; Kim, KS; Kim, SK; Koh, WS; Kwon, Y; Lee, ES; Nepal, MR; Noh, K; Park, S; Shrestha, A; Shrestha, R | 1 |
| Bian, X; Cai, Z; Jiang, Y; Kan, Z; Li, Y; Qian, H; Shi, W; Wang, Z; Zhou, J | 1 |
| Lee, J; Park, YH | 1 |
| Jung, A; Kirchner, T; Klauschen, F; Kumbrink, J; Li, P; Pók-Udvari, A | 1 |
| Martorana, F; Motta, G; Motta, L; Pavone, G; Vigneri, P | 1 |
| Naito, Y | 1 |
| Deluche, É; Vincent-Salomon, A | 1 |
| Campone, M; Frenel, JS; Mallet, A; Ombline, C; Robert, M | 1 |
| Funasaka, C; Harano, K; Hosono, A; Ishii, G; Kondoh, C; Kusuhara, S; Matsubara, N; Mitsunaga, S; Mukohara, T; Naito, Y; Nakai, T; Nakajima, H; Nakao, T | 1 |
| Funakoshi, S; Hayashi, T; Hirose, S; Hoshino, M; Machino, C; Ogura, N; Oikawa, H; Sakai, G; Satou, T | 1 |
| Jia, N; Yang, Q; Zhou, C; Zhou, X | 1 |
| Bako, E; Cathcart, J; Chiu, JWY; Chung, CF; Chung, WP; Cortés, J; Curigliano, G; Hamilton, E; Hegg, R; Huang, CS; Hurvitz, SA; Im, SA; Iwata, H; Kim, JH; Kim, MH; Kim, SB; Lee, C; Liu, Y; Park, YH; Pedrini, JL; Petry, V; Tseng, LM; Verma, S; Xu, B | 1 |
| Jacobson, A | 1 |
| Deng, J; Li, K; Tang, S; Wen, P; Yang, B | 1 |
| Abe, M; Ishikawa, H; Koyama, K; Murakami, M; Nakamaru, K; Qiu, Y; Shiose, Y; Ueno, S | 1 |
| Furuse, J; Hiraoka, N; Ikeda, M; Kawamoto, Y; Kobayashi, S; Komatsu, Y; Kuchiba, A; Matsui, N; Morizane, C; Nakamura, K; Nakamura, Y; Ohba, A; Okamoto, W; Okano, N; Okusaka, T; Sadachi, R; Sasaki, M; Ueno, M; Yoshida, H; Yoshino, T | 1 |
| Bardia, A; Brufsky, A; Cortés, J; Hamilton, E; Henry, S; Hurvitz, SA; Kalinsky, K; Leon-Ferre, R; Loirat, D; Mayer, I; O'Shaughnessy, J; Phan, S; Punie, K; Rugo, HS; Sardesai, S; Tolaney, SM; Traina, T; Zhu, Y | 1 |
| Blanch, S; Braga, S; Cejalvo, JM; Cortés, J; Cortez, P; de la Haba-Rodriguez, J; Fernández-Abad, M; Garrigós, L; Gion, M; Llombart-Cussac, A; Malfettone, A; Martinez-Bueno, A; Nave, M; Pérez-García, JM; Racca, F; Ruiz-Borrego, M; Sampayo-Cordero, M; Servitja, S; Vaz Batista, M | 1 |
| Armitage, M; Bardia, A; Harnden, K; Mauro, L; Pennisi, A; Soliman, H | 1 |
| Cameron, DA; Chae, YS; Gambhire, D; Gil-Gil, M; Gombos, A; Harbeck, N; Im, SA; Jacot, W; Kim, SB; Lee, KS; Li, W; Liu, Q; Luo, T; Meinhardt, G; Modi, S; Moore, HCF; Niikura, N; Park, YH; Pierga, JY; Prat, A; Rugo, HS; Saura, C; Schmid, P; Singh, J; Sohn, J; Sun, T; Tokunaga, E; Tsurutani, J; Ueno, NT; Vidal, M; Vitazka, P; Wang, X; Wang, Y; Xu, B; Yamashita, T; Yerushalmi, R; Yung, L; Zagouri, F | 1 |
| Beal, K; Modi, S; Moss, NS; Santomasso, BD; Tosi, U | 1 |
| Du, F; Yuan, P; Zheng, F | 1 |
| Cathcart, J; Cortés, J; Im, SA | 1 |
| Deng, Y; Gao, G; Jiang, YW; Liang, G; Liu, X; Sun, X; Tang, R; Xu, L; Zhan, W | 1 |
| DeMichele, A; Makhlin, I | 1 |
| Curigliano, G; Tarantino, P; Tolaney, SM | 2 |
| Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J | 1 |
| Huang, Y; Sheikh, MS | 1 |
| Bago-Horvath, Z; Bartsch, R; Bergen, ES; Berghoff, AS; Dieckmann, K; Forstner, H; Fuereder, T; Furtner, J; Gruenberger, B; Haslacher, H; Ilhan-Mutlu, A; Marhold, M; Minichsdorfer, C; Oehler, L; Preusser, M; Puhr, R; Roider-Schur, S; Rottenmanner, B; Singer, CF; Starzer, AM; Szekeres, T; Weltermann, A; Widhalm, G | 1 |
| Peng, Y; Tan, C; Wan, X; Wang, J; Yi, Y; Zeng, X | 1 |
| Bianchini, G; Cortes, J; Henning, JW; Rugo, HS; Untch, M | 1 |
| Bardia, A; Ciruelos, E; Cortes, J; Dalenc, F; Delaney, R; Fu, O; Jhaveri, KL; Lin, L; Loirat, D; Marmé, F; Pardo, PG; Rugo, HS; Schmid, P; Tolaney, SM; Trédan, O; Verret, W | 1 |
| Guo, W; Ma, X; Sun, J; Wang, Z; Xu, H; Zhang, H; Zhang, T; Zhong, X | 1 |
| Anders, CK; DiPiro, PJ; Gule-Monroe, M; Hsu, L; Hughes, M; Kabraji, S; Lascola, C; Li, T; Lin, NU; Moore, H; Murthy, RK; Ni, J; Pereslete, A; Raghavendra, AS; Sammons, S; Van Swearingen, AED; Wang, Y; Winer, EP; Zhao, JJ | 1 |
| Duits, AJ; Samson, MJ; Schnog, JB | 1 |
| Carroll, HK; Higgins, MJ; O'Reilly, S | 1 |
| Cameron, D; Gambhire, D; Modi, S | 1 |
| Andre, F; Cathcart, J; Gianni, L; Gonzàlez Farré, X; Hurvitz, SA; Jerusalem, G; Kim, SB; Krop, IE; Lee, C; Liu, Y; Modi, S; Murthy, RK; Osborne, CR; Park, YH; Perrin, C; Saura, C; Takano, T; Yamashita, T; You, B | 1 |
| Pellerino, A; Soffietti, R | 1 |
| Gogia, A; Sg, N | 1 |
| Vranic, S | 1 |
| Jiang, Y; Li, X; Liu, C; Wang, J; Xing, H; Zhang, Y | 1 |
| Grinda, T; Pistilli, B; Rassy, E | 1 |
| Deepak, V; Jeyaraman, A; Kabilan, SJ; Kumar, ASK; Kunjiappan, S; Pandian, SRK; Panneerselvam, T; Pavadai, P; Rajeshkumar, RR; Sundar, K; Vellaichamy, S | 1 |
| Gorgeu, V; Grellety, T | 1 |
| Chen, Y; Gao, Y; Hu, X; Li, C; Li, L; Ren, Z; Tong, W; Wang, J; Wang, X; Yao, W; Zhang, P | 1 |
| Chen, X; Kou, L; Li, J; Li, Y; Wen, Q; Xie, X | 1 |
| Bazhenova, L; Yun, KM | 1 |
| Sidaway, P | 1 |
| Dedić Plavetić, N; Križić, M; Popović, M; Silovski, T | 1 |
| Arumi, M; Cejalvo, JM; Ciruelos, E; Cruz, J; Esker, S; Espinosa-Bravo, M; Falato, C; Fan, PD; Ferrero-Cafiero, JM; González-Farré, B; Guerra, JA; Izarzugaza, Y; Luna, AM; Martínez-Sáez, O; Oliveira, M; Paré, L; Parul, P; Pascual, T; Pernas, S; Prat, A; Salvador-Bofill, FJ; Sanfeliu, E; Santhanagopal, A; Sellami, D; Tolosa, P; Vidal, M; Vila, MM; Villacampa, G | 1 |
| Bellesoeur, A; Bidard, FC; Champion, L; Seban, RD; Vincent-Salomon, A | 1 |
| Bako, E; Ciardiello, F; Di Bartolomeo, M; Elez, E; Fakih, M; Grothey, A; Kawakami, H; Kobayashi, K; Loupakis, F; Masuishi, T; Meinhardt, G; Nishina, T; Okuda, Y; Raghav, K; Rodriguez, J; Saxena, K; Siena, S; Wainberg, Z; Yamaguchi, K; Yoshino, T | 1 |
| Di Maio, M; Mosele, F | 1 |
| Alfaro, A; André, F; Bachelot, T; Baris, V; Christodoulidis, S; Deloger, M; Deluche, E; Diéras, V; Droin, N; Ducoulombier, A; Filleron, T; Garberis, IJ; Jimenez, M; Job, B; Kakegawa, T; Kannouche, P; Kobayashi, M; Lacroix, L; Lacroix-Triki, M; Laplante, P; Le Bescond, L; Levy, C; Lusque, A; Mahier, C; Marty, V; Mosele, F; Pistilli, B; Pradat, Y; Saulnier, P; Signolle, N; Stourm, A; Talbot, H; Tran, DTN; Vakalopoulou, M; Viret, F | 1 |
| Wang, D; Wei, T; Yuan, P | 1 |
| Al-Tweigeri, T | 1 |
| Del Re, M; Rolfo, C; Russo, A | 1 |
| Hoe, HJ; Solomon, BJ | 1 |
| Boland, F; Daly, GR; Dowling, GP; Hennessy, BT; Hill, ADK; Keelan, S; Toomey, S | 1 |
| Chen, J; Chen, M; Hou, Y; Jia, N; Li, R; Meng, W; Sun, B; Tang, X; Zhang, W | 1 |
| Chen, M; He, C; Tu, Y; Wan, JB; Wang, K | 1 |
| Bai, L; Chen, L; Guo, C; Guo, D; Jiang, P; Jiang, Z; Shi, J; Tong, R; Xu, Z; Yu, D; Zhu, Y | 1 |
| Agatsuma, T; Iwata, TN; Sugihara, K; Wada, T | 1 |
| Ge, XM; Li, JH; Liu, H; Liu, YM; Sun, XJ; Zhang, P; Zhen, YN | 1 |
| Algreen, L; Andersen, AB; Andersen, MB; Gromov, P; Gromova, I; Hansen, NY; Jakobsen, AK; Knudsen, BR; Kristoffersen, EL; Petersen, KW; Simonsen, AK; Stougaard, M; Tesauro, C | 1 |
| Andre, F; Aogi, K; Chen, S; Cortes, J; Denduluri, N; Hurvitz, SA; Im, SA; Ito, Y; Iwata, H; Kim, SB; Krop, I; Lee, C; Lee, KS; Modi, S; Park, YH; Perrin, C; Saura, C; Shahidi, J; Sohn, J; Tamura, K; Tokunaga, E; Tsurutani, J; Yamashita, T; Yver, A; Zhang, L | 1 |
| Davis, ME; Wyatt, EA | 1 |
| Doi, T; Fujisaki, Y; Iwata, H; Krop, IE; Lee, C; Modi, S; Moreno-Aspitia, A; Murthy, RK; Park, H; Redfern, C; Sagara, Y; Shahidi, J; Sugihara, M; Takahashi, S; Tamura, K; Tsurutani, J; Zhang, L | 2 |
| Agatsuma, T; Soria, JC; Yver, A | 1 |
| Cifuentes-Rius, A; Howard, CB; Hutmacher, DW; Janowicz, PW; Kaur, I; Lahr, CA; Landgraf, M; McGovern, JA; Ravichandran, A; Sanchez-Herrero, A; Shafiee, A; Voelcker, NH | 1 |
| Aschenbrenner, DS | 1 |
| André, F; Arteaga, C; Bardia, A; Cortes, J; Delaney, RJ; Hafeez, A; Hong, Q; Marmé, F; Rugo, HS; Schmid, P; Sohn, J; Tolaney, SM | 1 |
| Huang, Q; Jiang, W; Li, K; Lyu, M; Suo, M; Zhu, D | 1 |
| Chang, CF; Chen, YC; Chiu, CC; Chiu, CF; Hung, SW; Lin, YQ; Park, JM | 1 |
| Syed, YY | 1 |
| Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C | 1 |
| Rugo, HS | 1 |
| Dekker, TJA | 1 |
| Bartsch, R | 1 |
| Anderson, CF; Cui, H; Dai, W; Oh, R; Su, H; Wan, F; Wang, F; Wang, Z; Xu, D; Zhang, W; Zheng, M | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Andrikopoulou, A; Dimopoulos, MA; Koutsoukos, K; Liontos, M; Zagouri, F; Zografos, E | 1 |
| Abramson, VG; Bardia, A; Diamond, JR; Goldenberg, DM; Goswami, T; Hong, Q; Juric, D; Kalinsky, K; Maliakal, P; Mayer, IA; Moroose, RL; O'Shaughnessy, J; Sharkey, RM; Tolaney, SM; Vahdat, LT; Wegener, WA | 1 |
| Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W | 1 |
| Gelmon, KA; Tesch, ME | 1 |
| Sharma, P; Stecklein, SR | 1 |
| Hao, Q; Hu, X; Lu, S; Wang, W; Wang, Z; Wen, L; Xing, D; Zhan, M; Zhao, W | 1 |
| AbuTarif, M; Endo, S; Garimella, T; LaCreta, F; Wada, R; Xiong, Y; Yin, O; Yoshihara, K | 1 |
| Cardoso, F; Cortes, J; Curigliano, G; Prat, A; Tarantino, P | 1 |
| Kamio, T; Kamiyama, E; Kaneko, R; Muto, R; Saito, K; Sugihara, M | 1 |
| Lambertini, M; Punie, K | 1 |
| Lin, S; Liu, H; Mo, R; Shen, S; Xu, X; Zhang, C; Zhang, Y | 1 |
| Exman, P; Tolaney, SM | 1 |
| Fukasawa, Y; Funasaka, C; Harano, K; Hosono, A; Kondoh, C; Kusuhara, S; Kuwata, T; Matsubara, N; Mimaki, S; Mukohara, T; Naito, Y; Nakao, T; Nakayama, A; Tsuchihara, K | 1 |
| Borlagdan, JP; Hooper, M; Nguyen, X; Palumbo, A | 1 |
| Dixon, JM; Gray, M; Kay, C; Martínez-Pérez, C; Meehan, J; Turnbull, AK; Webber, V | 1 |
| Hugo, HS | 1 |
| Amiri-Kordestani, L; Beaver, JA; Chiu Yuen Chow, E; Chiu, HJ; Goldberg, KB; Guiterrez-Lugo, M; Hou, S; Namuswe, F; Narayan, P; Osgood, CL; Pazdur, R; Pierce, WF; Qiu, J; Ricks, TK; Singh, H; Song, P; Tang, S; Theoret, MR; Yu, J | 1 |
| Cortés, J; Garrigós, L; Gion, M; Jänne, PA; Perez, J; Shitara, K; Siena, S | 1 |
| AbuTarif, M; Garimella, T; Iwata, H; Kastrissios, H; LaCreta, F; Lee, C; Lin, CC; Shahidi, J; Tamura, K; Wada, R; Watanabe, J; Yin, O; Zhang, L | 1 |
| Bellesoeur, A; Minot-This, MS | 1 |
| Ganguly, S; Gogia, A | 1 |
| Bardia, A; Hurvitz, SA; Rugo, HS | 1 |
| Liang, JF; Zhan, H | 1 |
| Chen, D; Deng, H; Huang, P; Jin, X; Sun, P; Wang, N; Zhu, X | 1 |
| Keyvani-Ghamsari, S; Rabbani-Chadegani, A; Sargolzaei, J; Shahhoseini, M | 1 |
| Agatsuma, T | 1 |
| Sahota, S; Vahdat, LT | 1 |
| Chang, XF; Chen, HY; Guan, QY; Kang, B; Li, SS; Meng, G; Wang, P; Wei, JW; Xu, JJ | 1 |
| Kandasamy, R; Natesan, S; Palanichamy, R; Ponnusamy, C; Sugumaran, A; Thiagarajan, V | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Abdel-Rahman, WM; Al-Khayyal, NA; Aravind, SR; Nair, VA; Saber-Ayad, M | 1 |
| Kandasamy, P; Kandasamy, R; Krishnaswami, V; Lakshmanan, M; Natesan, S; Palanichamy, R; Ponnusamy, C; Sugumaran, A | 1 |
| Bo, M; Chen, B; Chen, M; Gao, S; Li, L; Ma, Q; Yuan, K; Zhang, W; Zhu, L | 1 |
| Jeon, NL; Kim, SY; Min, DH; Park, S; Samson, AAS; Song, JM | 1 |
| Li, P; Ran, H; Ren, J; Wang, Z; Xia, Y; Zhao, H; Zhou, Z; Zhu, L | 1 |
| Ji, L; Jiang, G; Liu, R; Liu, Z; Ma, Q; Yang, Y; Yang, Z; Zhao, H | 1 |
| Agatsuma, T; Ishida, S; Ishii, C; Iwata, TN; Ogitani, Y; Wada, T | 1 |
| Chen, Y; Fan, Z; Hou, Z; Li, Y; Lin, J; Ma, J; Su, G; Xie, L; Zhang, H; Zhang, Y; Zhu, X | 1 |
| Chen, X; Gao, C; He, Z; Hua, B; Huang, F; Huang, X; Jacobson, O; Liu, Y; Mao, Z; Wang, W; Wang, Z; Yu, C; Yu, G; Zhang, F; Zhao, X; Zhou, J; Zhu, X | 1 |
| Wang, X; Yan, XP | 1 |
| Cao, Q; Ji, LN; Mao, ZW; Yang, GG; Yang, J; Zhang, DY; Zhang, H | 1 |
| Chiu, CC; Chou, CK; Dahms, HU; Hsi, E; Huang, HW; Kuo, PL; Liang, SS; Tsai, EM; Wang, TN; Yang, CF | 1 |
| El-Sayed, NS; Parang, K; Park, SE; Sajid, MI; Shirazi, AN; Tiwari, RK | 1 |
| Lin, LT; Liu, CH; Pan, YC; Richardson, CD; Tai, CJ; Wong, SH | 1 |
| Doi, T; Iwata, H; Jikoh, T; Krop, IE; Lee, C; Modi, S; Murthy, RK; Park, H; Redfern, C; Redman, RA; Sagara, Y; Shahidi, J; Sugihara, M; Takahashi, S; Tamura, K; Tsurutani, J; Yver, A | 1 |
| Giannone, G; Montemurro, F | 1 |
| Li, Y; Liang, S; Lu, H; Xu, S | 1 |
| Hou, C; Jia, D; Kang, Y; Lu, Y; Ma, X; Wang, Y; Xu, Z; Xue, P; Zhang, T; Zu, M | 1 |
| Gao, X; Ji, J; Li, M; Lv, J; Mao, W; Sun, C; Wang, J; Yang, W; Zhang, L; Zhao, Z | 1 |
| Chen, HL; Chen, YL; Lee, YC; Liu, YP; Lo, CW; Lu, PJ; Tseng, CH; Tzeng, CC; Yang, CN | 1 |
| Jonasch, E; Jope, RS; Sun, M; Zhou, T | 1 |
| Ganeshaiah, KN; Kumar, TR; Priti, V; Ramesha, BT; Ravikanth, G; Senthilkumar, U; Shaanker, RU; Suma, HK; Vasudeva, R | 1 |
| Jiang, Q; Liu, J; Luo, X; Yang, Z; Zhang, X | 1 |
| Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U | 1 |
| Balogh, D; Nechushtai, R; Sung, SY; Wang, F; Willner, I; Zhang, Z | 1 |
| Acevedo-Morantes, CY; Acevedo-Morantes, MT; Ramírez-Vick, JE; Suleiman-Rosado, D | 1 |
| Barua, S; Mitragotri, S | 1 |
| Brünner, N; Nielsen, DL | 1 |
| Awada, A; Barrett-Lee, PJ; Chan, S; Chia, YL; Cocquyt, V; Coleman, RE; Garcia, AA; Hamm, JT; Hannah, AL; Hoch, U; Huizing, MT; Jerusalem, GH; Mehdi, A; O'Reilly, SM; Perez, EA; Sideras, K; Young, DE; Zhao, C | 1 |
| Ang, WT; Ho, GH; Koh, QM; Koong, HN; Lin, VC; Sivaramakrishnan, G; Sun, Y | 1 |
| Iwase, H; Kitabatake, M; Kuwahara, K; Moolthiya, P; Phimsen, S; Rezano, A; Sakaguchi, N; Suda, T; Tone, S; Yamamoto, Y; Yamamoto-Ibusuki, M | 1 |
| Dai, W; Gemeinhart, RA; Li, T; Wang, X; Zhang, H; Zhang, Q | 1 |
| Cao, DY; Dun, JN; Fang, Y; Wang, J; Xiang, B; Xue, GQ; Zhang, L | 1 |
| Bobilev, D; Peleg, R; Priel, E | 1 |
| Chen, Z; Feng, Y; Guo, R; He, M; Hong, Z; Kong, X; Li, M; Li, Y; Tian, R; Wang, J; Wu, W; Yu, K; Yu, M | 1 |
| Choene, MM; Moela, P; Motadi, LR | 1 |
| Cheetham, AG; Cui, H; Ou, YC; Zhang, P | 1 |
| Chandrashekaran, V; Chen, H; Cheng, B; Montgomery, J; Peña, MM; Remant, BK; Xu, P; Zhang, J | 1 |
| Inaba, T; Ishida, K; Kashiwaba, M; Kawagishi, R; Komatsu, H; Matsui, Y; Sugai, T; Uesugi, N; Wakabayashi, G | 1 |
| Altieri, DC; Bosari, S; Faversani, A; Lopergolo, A; Moro, GP; Rivadeneira, D; Schultz, DC; Tosi, D; Vaira, V | 1 |
| Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M | 1 |
| Girija, G; Jeevanesan, V; Natesan, S; Palanichamy, R; Ponnusamy, C; Sugumaran, A | 1 |
| Chen, M; Li, X; Luo, X; Wei, J; Zhang, H; Zhang, Y | 1 |
| Mishra, MN; Palakurthi, S; Vangara, KK | 1 |
| Apte, RN; Kogan-Zviagin, I; Peleg, R; Priel, E; Romzova, M | 1 |
| Lan, H; Li, Y; Lin, CY | 1 |
| Fox, JL; Storey, A | 1 |
| Hayakawa, Y; Lou, C; Saiki, I; Yokoyama, S | 1 |
| Balslev, E; Brünner, N; Kümler, I; Nielsen, D; Stenvang, J | 1 |
| Amzerin, M; Errihani, H; Mokrim, M; Piccart, MJ | 1 |
| Chen, F; Kumar, A; Liang, XJ; Pan, Y; Xue, X; Zhang, X; Zhao, Y | 1 |
| Ghazwani, M; Huang, Y; Li, S; Liu, C; Lu, J; Ma, X; Wang, P; Xu, J; Zhang, P | 1 |
| Cuddington, BP; Ketela, T; Moffat, J; Mossman, KL; Workenhe, ST | 1 |
| Advani, PP; Crozier, JA; Hobday, T; Jaslowski, AJ; LaPlant, B; Moreno-Aspitia, A; Perez, EA | 1 |
| Adkins, CE; Eldon, MA; Hoch, U; Hye, T; Lockman, PR; Mohammad, AS; Mohan, NK; Nounou, MI; Terrell-Hall, T | 1 |
| Bortner, CD; Ehrenshaft, M; Kumar, A; Kumari, A; Mason, RP; Sharma, NK; Sinha, BK; Tokar, EJ; Waalkes, MP; Williams, J | 1 |
| Ki, J; Shim, Y; Song, JM | 1 |
| Aluzaite, K; Brünner, N; Damsgaard, B; Do, KN; Foekens, J; Fogh, L; Gajjar, M; Hamerlik, P; Hansen, SN; Jandu, H; Knudsen, BR; Martens, J; Moreira, J; Nielsen, SL; Noer, JB; Pommier, Y; Proszek, J; Schrohl, AS; Smid, M; Stenvang, J; Stougaard, M; Thrane, SW | 1 |
| Dixit, M; Potunuru, UR; Srivastava, S; Venugopalan, A | 1 |
| Bartlett, JM; Boutros, PC; Braunstein, M; Kalatskaya, I; Krzyzanowski, PM; Liao, L; Lobo, N; Lyttle, N; Marcellus, R; Spears, M; Stein, LD; Taylor, KJ; Twelves, CJ; Yao, CQ | 1 |
| Agarwal, D; Aleskandarany, MA; Arora, A; Ball, G; Bohr, VA; Croteau, DL; Ellis, IO; Lu, H; Madhusudan, S; Pommier, Y; Shamanna, RA | 1 |
| Abe, Y; Agatsuma, T; Aida, T; Arakawa, S; Atsumi, R; Hagihara, K; Harada, N; Hayakawa, I; Hirai, T; Ishii, C; Nakada, T; Ogitani, Y; Oitate, M; Okamoto, H; Soma, M; Yamaguchi, J | 1 |
| Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G | 1 |
| Li, Q; Liang, H; Sun, B; Wang, W; Xu, J; Zeng, Z; Zhao, X | 1 |
| Agatsuma, T; Hagihara, K; Naito, H; Ogitani, Y; Oitate, M | 1 |
| Bocci, G; Kerbel, RS | 1 |
| Cardillo, TM; Chang, CH; Goldenberg, DM; Liu, D; Wang, Y; Zalath, M | 1 |
| Billadeau, DD; Cristofanilli, M; Cryns, VL; Gaisina, I; Giles, F; Jain, S; Kozikowski, A; Mazar, AP; O'Halloran, T; Ugolkov, A; White, K; Zhang, JS | 1 |
| Bong, D; Green, D; Munyaradzi, O; Xia, X; Zhou, Z | 1 |
| Barua, D; Barua, S; Brocker, C; Dunlap, K; Forciniti, D; Huang, YW; Kim, HH; Laemthong, T | 1 |
| Deshpande, NU; Jayakannan, M | 1 |
| Abe, N; Abe, S; Aoto, K; Kawana, S; Murakami, F; Ohtake, T; Okano, M; Suzuki, O; Tachibana, K; Takenoshita, S; Tasaki, K | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Desai, SD; Giovanella, BC; Hsieh, TS; Liu, LF; Marks, JR; Scott, GL; Tsai, YC; Wood, LM | 1 |
| Stebbing, J | 1 |
| Choi, J; Gump, J; Lacevic, M; Lee, JH; Lush, R; Minton, S; Moulder, S; Munster, P; Neuger, A; Sullivan, D; Valkov, N | 1 |
| Gan, L; Gan, Y; Pan, WS; Zhang, XX; Zhu, CL | 1 |
| Algeciras-Schimnich, A; O'Kane, DJ; Snozek, CL | 1 |
| Baki, M | 1 |
| Kawakami, I; Kobayashi, Y; Kohyama, N; Ohbayashi, M; Yamamoto, T; Yasuda, M | 1 |
| Bayani, N; Bhattacharya, S; Bissell, MJ; Das, D; Feiler, HS; Gascard, P; Gendelman, R; Gray, JW; Guan, Y; Heiser, LM; Hu, Z; Knight, Z; Korn, WM; Kuo, WL; McCormick, F; Mills, GB; Mirzoeva, OK; Neve, RM; Parvin, B; Shokat, KM; Siwak, D; Spellman, PT; Wang, NJ; Wyrobek, AJ | 1 |
| Abbruscato, TJ; Alfonso, LF; Arumugam, TV; Bhat, GJ; Srivenugopal, KS; Weidanz, JA | 1 |
| Greenchurch, KB; Kanagasabai, R; Liu, S; Salama, S; Snapka, RM; Yamasaki, EF; Zhang, L | 1 |
| Caplen, NJ; Jones, TL; Martin, SE; Pommier, Y; Zhang, YW | 1 |
| Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Souda, M; Tanaka, K; Yamamoto, Y | 1 |
| Cai, M; Chen, L; Chowdhury, D; Gao, M; Lee, DH; Li, J; Liao, J; Pfeifer, GP; Wang, H; Xu, X; Yang, YG; Yen, Y; Zhao, A; Zhong, X | 1 |
| Abu-Ghanem, S; Livneh, E; Oberkovitz, G; Rotem-Dai, N | 1 |
| Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW | 1 |
| Aiba, K; Arakawa, Y; Saito, S; Yamada, H | 1 |
| Choi, K; Rineer, J; Sanmugarajah, J | 1 |
| Ames, MM; Goetz, MP; Kuffel, MJ; Reinicke, KE | 1 |
| Bear, HD; Di, X; Gennings, C; Gewirtz, DA; Graham, LJ; Sheth, CM; White, KL | 1 |
| Ferreira, J; Parra, E | 1 |
| Fushimi, K; Kumagai, K; Nakano, S; Yamamoto, N | 1 |
| Gu, J; He, Q; Li, Y; Shi, J; Su, S | 1 |
| Arnaud, O; Bates, SE; Boumendjel, A; Di Pietro, A; Dumontet, C; Falson, P; Gèze, A; Guitton, J; Honorat, M; Matera, EL; Payen, L; Stein, WD | 1 |
| Eilertsen, K; Jeansonne, DP; Kirk-Ballard, H; Koh, GY; Liu, D; Liu, Z; Wolff, L; Zhang, F | 1 |
| Aoki, M; Fujii, M; Murata, T; Oda, K | 1 |
| Hede, K | 1 |
| Hou, W; Li, J; Liao, J; Liu, J; Liu, X; Stark, JM; Wang, J; Wang, P; Xie, Y; Xu, X; Yao, L; Zhong, J; Zhu, B | 1 |
| Caplen, NJ; Gehlhaus, K; Guha, R; Jones, TL; Martin, SE; Miyamoto, S; Pommier, Y; Wu, ZH; Zhang, YW | 1 |
| Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S | 1 |
| Hayashi, H; Masuda, N; Miyazaki, M; Morinaga, R; Nakagawa, K; Nakayama, T; Nishida, Y; Okamoto, I; Okamoto, W; Sakamoto, J; Satoh, T; Terashima, M; Tokunaga, Y; Tominaga, S; Tsurutani, J; Yamaguchi, M | 1 |
| Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
| Aft, RL; Cai, S; Ellis, MJ; Goiffon, RJ; Guo, Z; Hoog, J; Li, S; Lin, L; Ma, CX; Piwnica-Worms, H; Prat, A; Ryan, CE; Schaiff, WT | 1 |
| Kanomata, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Shimo, T; Sonoo, H; Yamashita, T | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Choi, KC; Choi, KJ; Kim, SU; Yi, BR | 1 |
| Jayaprakasha, GK; Patil, B; Pearce, K; Price, J; Shuck, R; Somasundaram, S | 1 |
| Ambudkar, SV; Bhatnagar, J; Chen, JJ; Chen, WM; Chen, ZS; Lan, P; Ruan, ZX; Shu, C; Sodani, K; Wang, J; Xiao, ZJ; Ye, WC; Zhang, DM | 1 |
| Bernard, PS; Brenin, CM; Cai, SR; Craig Lockhart, A; Creekmore, AN; Dancey, J; Doyle, LA; Ebbert, M; Ellis, MJ; Fracasso, PM; Guo, Z; Ma, CX; Mwandoro, T; Naughton, MJ; Petroni, GR; Picus, J; Piwnica-Worms, H; Pluard, TJ; Reed, J; Ryan, CE; Watson, M; Yarde, ER | 1 |
| Huang, J; Mao, W; Shen, Y; Sui, M; Wang, J; Wu, X; Zhang, H | 1 |
| Shimada, T; Watanabe, A | 1 |
| Chauvier, D; Kegelaer, G; Manfait, M; Morjani, H | 1 |
| Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH | 1 |
| Budman, DR | 1 |
| Banerjee, D; Bertino, JR; Brennan, MF; Chou, TC; Guan, Y; Li, W; Scotto, KW; Takahashi, N; Wada-Takahashi, Y | 1 |
| Caiolfa, VR; Castelli, MG; D'Argy, R; Farao, M; Fiorino, A; Fontana, E; Ghiglieri, A; Gratton, E; Pesenti, E; Suarato, A; VandeVen, M; Zamai, M | 1 |
| Aguirre, A; Diáz-González, F; Dorta, J; Fernández, JJ; Moser-Thier, K; Pec, MK; Souto, ML; Villar, J | 1 |
| Agelaki, S; Alexopoulos, A; Ardavanis, A; Georgoulias, V; Kalbakis, K; Karyda, E; Kouroussis, Ch; Malamos, N; Malas, K; Tselepatiotis, E | 1 |
| Adams, DJ; Colvin, OM; Dewhirst, M; Driscoll, TA; Flowers, JL; Friedman, HS; Hoffman, RM; Manikumar, G; Wall, ME; Wani, MC | 1 |
| Shapiro, CL; Xu, Y | 1 |
| Nyormoi, O; Satoh, TH; Surmacz, TA; Whitacre, CM | 1 |
| Bowen, JM; Cummins, AG; Gibson, RJ; Inglis, MR; Keefe, DM | 1 |
| Colucci, P; Cristofanilli, M; DeJager, R; Duggal, A; Esteva, FJ; Hortobagyi, GN; Rivera, E; Royce, M; Valero, V | 1 |
| Asim, M; Chen, X; Shankar, S; Singh, TR; Srivastava, RK | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Gao, S; Scott, RE | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Guiney, P; Haney, LG; Lenaz, L; Miller, KD; Murry, DJ; Sledge, GW; Soule, SE; Sun, SL | 1 |
| Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
| Conticello, C; De Maria, R; Messina, A; Patti, M; Pedini, F; Peschle, C; Stassi, G; Zerilli, M; Zeuner, A | 1 |
| Dakhil, SR; Fitch, TR; Hillman, DW; Ingle, JN; Kardinal, CG; Krook, JE; Kugler, JW; Mailliard, JA; Perez, EA; Rowland, KM; Ryan, JM | 1 |
| Gajda, J; Gajkowska, B; Wojewódzka, U | 1 |
| Bjornsti, MA; de Jong, LA; Jansen, LE; Pluim, D; Schellens, JH; van Eijndhoven, MA; van Waardenburg, RC; Verseyden, C | 1 |
| Gajkowska, B; Godlewski, MM; Gorka, M; Motyl, T; Wojewodzka, U | 1 |
| Paukstadt, W | 1 |
| Cao, ZS; Dejesus, A; Giovanella, B; Mendoza, J | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Chen, SZ; Jiang, M; Zhen, YS | 1 |
| Di, X; Dumur, C; Elmore, LW; Gewirtz, DA; Holt, SE | 1 |
| Arima, T; Horino, K; Inoue, M; Kaneda, H; Kimura, M; Kuhara, H; Kume, S; Nakano, M; Nishimura, T; Uemura, K | 1 |
| Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J | 1 |
| Berchtold, C; Chang, PY; Miyamoto, S; Wuerzberger-Davis, SM | 1 |
| Adams, DJ; Colvin, M; Dewhirst, MW; Flowers, JL; Manikumar, G; Sen, B; Wahl, ML; Wani, MC | 1 |
| André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; D'Aniello, R; De Rosa, V; Di Bonito, M; Frasci, G; Giordano, R; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Bevins, RL; Zimmer, SG | 1 |
| Gajkowska, B; Lamparska-Przybysz, M; Motyl, T | 1 |
| Adams, DJ; Colvin, OM; da Silva, MW; Flowers, JL; Kohlhagen, G; Manikumar, G; Pommier, Y; Wani, MC | 1 |
| Chedid, S; Cristofanilli, M; Esteva, F; Frye, DK; Hortobagyi, G; Ibrahim, N; Mettinger, KL; Rivera, E; Valero, V | 1 |
| Amano, S; Enomoto, K; Negishi, N; Sakurai, K | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Bartlett, DW; Cheng, J; Davis, ME; Heidel, JD; Hollister, B; Hwang, J; Schluep, T | 1 |
| Bailly, C; Beauvillain, JC; Cuevas, C; Gallego, MA; Kluza, J; Loyens, A; Marchetti, P; Sousa-Faro, JM | 1 |
| Drummond, DC; Guo, Z; Hong, K; Kirpotin, DB; Noble, CO; Park, JW | 1 |
| Chao, P; Hu, P; Lalloo, A; Sinko, PJ; Stein, S | 1 |
| Fujii, Y; Nakazawa, K; Shuzui, Y; Yoneto, T | 1 |
| Abedin, MJ; Kelekar, A; Lehmann, U; McDonnell, MA; Wang, D | 1 |
| Abiri, SO; Apostolov, EO; Basnakian, AG; Shah, SV; Singh, AB; Stewart, AG; Yin, X | 1 |
| Carnahan, MA; Grinstaff, MW; Griset, AP; Kroll, DJ; Manikumar, G; Morgan, MT; Nakanishi, Y; Oberlies, NH; Wani, MC; Wathier, M | 1 |
| Koo, OM; Onyuksel, H; Rubinstein, I | 1 |
| Creaven, P; Levine, E; O'connor, T; Rustum, Y | 1 |
| Allen, WL; Galligan, L; Johnston, PG; Longley, DB; Rogers, KM; Sakai, H; Thomas, M; Wilson, TR | 1 |
| Komatsu, N; Makuuchi, H; Matsui, N; Mukai, M; Nakamura, M; Nakasaki, H; Ninomiya, H; Sato, S; Wakui, K | 1 |
| Coy, DH; Fuselier, JA; Jensen, RT; Mantey, SA; Moody, TW | 1 |
| Górka, M; Lamparska-Przybysz, M; Motyl, T | 1 |
| Boku, N; Yamazaki, K; Yoshino, T | 1 |
| Gong, JP; He, XJ; Li, XL; Qiu, FZ; Tao, DD; Wu, YQ; Xia, Y; Yuan, HL; Zhang, L | 1 |
| Bachelot, T; Biron, P; Blay, JY; Brantus, JF; Confavreux, C; Ghesquière, H; Guastalla, JP; Ray-Coquard, I; Rustam, F; Saba, C; Sebban, C | 1 |
| Gao, Y; Li, LB; Zhai, G | 1 |
| Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H | 1 |
| Allen, J; Kolesar, J; Mrozek, E; Shapiro, CL; Villalona-Calero, M; Young, D | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Boothman, DA; Church, DR; Frydman, B; Hutson, P; Planchon, SM; Wilding, G; Witiak, DT; Wuerzberger, S | 1 |
| Cowan, KH; Horton, JK; Schneider, E; Yang, CJ | 1 |
| Taguchi, T | 1 |
| Daoud, SS; Fetouh, MI; Giovanella, BC | 1 |
| Giovanella, BC; Kozielski, AJ; Pantazis, P; Petry, ER; Vardeman, DM | 1 |
| Doihara, H; Takashima, S; Yokoyama, N | 1 |
| Ishida, T; Morimoto, K; Ogawa, M; Ogawa, N; Taguchi, T; Tominaga, T | 1 |
| Ara, G; Eder, JP; Herman, TS; Holden, SA; Korbut, T; Schwartz, GN; Teicher, BA | 1 |
| Ishida, T; Izuo, M; Nakao, I; Ogawa, M; Oguro, M; Ohkawa, T; Taguchi, T; Tominaga, T; Yoshida, M; Yoshida, Y | 1 |
| Early, JA; Giovanella, BC; Hinz, HR; Kozielski, AJ; Mendoza, JT; Pantazis, P | 1 |
| Sinha, BK; Wang, Z | 1 |
| Keith, WN; McLeod, HL | 1 |
| Fujimori, A; Gupta, M; Hoki, Y; Pommier, Y | 1 |
| Clements, MK; Daoud, SS; Wasi, S | 1 |
| Bryant, M; Eder, JP; Grossbard, M; Huberman, M; Hurwitz, S; Kinchla, N; Kufe, DW; Lynch, T; Rodriguez, D; Rubin, E; Schnipper, L; Shapiro, C; Shulman, L; Stone, R; Supko, J; Toppmeyer, D; Vosburg, E; Xu, G | 1 |
| Barrett, JC; Dunn, SE; Hardman, RA; Kari, FW | 1 |
| Armand, JP; Couteau, C; Terret, C | 1 |
| Clements, MK; Daoud, SS; Jones, CB; Wasi, S | 2 |
| Enomoto, K | 1 |
| Liu, W; Zhang, R | 1 |
| Boothman, DA; Bornmann, WG; Byers, KL; Pink, JJ; Planchon, SM; Wuerzberger, SM | 1 |
| Cushman, M; Kohlhagen, G; Nagafuji, P; Paull, KD; Pommier, Y | 1 |
| Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
| Fornari, FA; Gewirtz, DA; Jain, PT; Orr, MS; Randolph, JK | 1 |
| Rosen, LS | 1 |
| Fan, S; Gupta, M; Kohn, KW; O'Connor, PM; Pommier, Y; Zhan, Q | 1 |
| Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
| Darzynkiewicz, Z; Degraef, C; Del Bino, G; Fokan, D; Galand, P; Mosselmans, R | 1 |
| Nieves-Neira, W; Pommier, Y | 1 |
| Mangold, G; Manikumar, G; Marty, J; Potter, PM; Vladu, B; Von Hoff, DD; Wadkins, RM; Wall, ME; Wani, MC; Weitman, S | 1 |
| Gobert, C; Larsen, AK; Skladanowski, A | 1 |
| Leung, LK; Wang, TT | 1 |
| Cameron, IL; Hardman, WE; Moyer, MP | 1 |
| Bedner, E; Cheng, W; Darzynkiewicz, Z; Deptala, A; Li, X; Traganos, F | 1 |
| Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C | 1 |
| Balcerzak, SP; Kraut, EH; Kuebler, JP; Mayernik, DG; O'Rourke, MA; Petrus, JJ; Young, D | 1 |
| Baldwin, AS; Cusack, JC; Liu, R | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Harada, M; Imai, J; Kawaguchi, T; Kiuchi, S; Okuno, S; Sakamura, Y; Tsuda, N; Tsujihara, K; Yano, S; Yano, T | 1 |
| Gilbert, B; Giovanella, BC; Kleinerman, E; Knight, V; Koshkina, N; Waldrep, C | 1 |
| Jeng, J; Wang, TT | 1 |
| Gamucci, T; Hanauske, A; Heinrich, B; Kaye, S; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Sessa, C; Verweij, J; Wanders, J | 1 |
| Bedner, E; Darzynkiewicz, Z; Kunicki, J; Li, X | 1 |
| Kinoshita, H; Kou, M; Morimoto, K | 1 |
| Clements, MK; Daoud, SS; Jones, CB; Redkar, A | 1 |
| Adams, DJ; Colvin, OM; Dewhirst, MW; Flowers, JL; Gamcsik, MP; Manikumar, G; Wall, ME; Wani, MC | 1 |
| Chen, X; Danes, C; Hall, MJ; Herliczek, T; Keyomarsi, K; Lawrence, DA; Lowe, M | 1 |
| Cao, Z; Early, J; Giovanella, B; Harris, N; Kozielski, A; Liehr, J; Mendoza, J; Pantazis, P; Stehlin, JS; Vardeman, D | 1 |
| Firby, PS; Horn, L; Li, ML; Moore, MJ | 1 |
| Prescott, LM | 1 |
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| Desai, SD; Li, TK; Liu, LF; Rodriguez-Bauman, A; Rubin, EH | 1 |
| Chen, X; Jiang, J; Nozell, S; Wang, J; Zhou, W; Zhu, J | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Itoh, K; Minami, H; Saeki, T; Sasaki, Y; Shigeoka, Y | 1 |
| Agrawal, S; Nan, L; Wang, H; Yu, D; Zhang, R | 1 |
| Baumgarten, J; Fiebig, HH; Kempka, G; Lehmann, TE; Lerchen, HG; Sperzel, M; von dem Bruch, K | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Cummings, J; Jardine, L; Joel, SP; Okorokov, AL; te Poele, RH | 1 |
| Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
| Ciftci, K; Su, J | 1 |
| Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
| Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Chauvier, D; Manfait, M; Morjani, H | 1 |
| Edmund, NA; Moore, DT; Orlowski, RZ; Shi, YY; Small, GW; Somasundaram, S | 1 |
| Donehower, RC; Grochow, LB; Hendricks, CB; Kaufmann, SH; Rowinsky, EK | 1 |
| Hawkins, MJ | 1 |
| Furue, H; Hasegawa, K; Hattori, T; Niitani, H; Ohta, K; Taguchi, T; Wakui, A | 1 |
43 review(s) available for camptothecin and Breast Cancer
| Article | Year |
|---|---|
Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Topics: Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2022 |
A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasms | 2021 |
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Gene Amplification; Genes, erbB-2; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Receptor, ErbB-2; Trastuzumab | 2021 |
Topics: Ado-Trastuzumab Emtansine; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Immunoglobulin G; Neoadjuvant Therapy; Oligopeptides; Peptide Fragments; Receptor, ErbB-2; Trastuzumab | 2021 |
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Immunoconjugates; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab | 2022 |
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Topics: Alopecia; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Fatigue; Female; Humans; Immunoconjugates; Lung Diseases, Interstitial; Nausea; Neutropenia; Trastuzumab; Ventricular Dysfunction, Left; Vomiting | 2022 |
Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2023 |
The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Fam-Trastuzumab Deruxtecan (Enhertu) Induced Pyloric Perforation in Hormone Receptor-positive/HER2-low Expresses Metastatic Breast Cancer.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Intestinal Perforation; Receptor, ErbB-2; Trastuzumab | 2023 |
Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis.
Topics: Anemia; Breast Neoplasms; Camptothecin; Female; Humans; Neutropenia; Receptor, ErbB-2; Trastuzumab | 2023 |
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2019 |
Sacituzumab Govitecan: First Approval.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Approval; Female; Humans; Immunoconjugates; Molecular Structure; Triple Negative Breast Neoplasms | 2020 |
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2020 |
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Breast Neoplasms; Bystander Effect; Camptothecin; Disease Progression; Female; Humans; Immunoconjugates; Molecular Targeted Therapy; Prognosis; Receptor, ErbB-2; Trastuzumab | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Development; Female; Humans; Immunoconjugates; Trastuzumab; United States; United States Food and Drug Administration | 2021 |
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2020 |
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Kaplan-Meier Estimate; Oxazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2021 |
HER2-positive metastatic breast cancer: a comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2021 |
A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2021 |
Current trends in the treatment of HR+/HER2+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Receptor Antagonists; Female; Humans; Immunoconjugates; Mastectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2021 |
Development of New ADC Technology with Topoisomerase I Inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Cysteine; Drug Delivery Systems; Drug Discovery; Humans; Immunoconjugates; Molecular Targeted Therapy; Rats; Receptor, ErbB-2; Topoisomerase I Inhibitors; Trastuzumab | 2017 |
Sacituzumab govitecan: an antibody-drug conjugate.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms | 2017 |
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2013 |
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.
Topics: Administration, Metronomic; Alkylating Agents; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Forecasting; Humans; Immunity, Cellular; Pyrimidines; Randomized Controlled Trials as Topic; Tubulin Modulators | 2016 |
[A Case of Primary Poorly Differentiated/Small Cell Carcinoma of the Breast in a Patient with Von Recklinghausen's Disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neurofibromatosis 1 | 2016 |
Pharmacogenomics of tamoxifen and irinotecan therapies.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen; Treatment Outcome | 2008 |
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
Topics: Breast Neoplasms; Camptothecin; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Ganciclovir; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Humans; Irinotecan; Prodrugs; Stem Cells; Thymidine Kinase | 2012 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Rationale for mitomycin and irinotecan use in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mitomycin; Women's Health | 2003 |
[Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoembryonic Antigen; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Skin Neoplasms | 2005 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fluorouracil; Humans; Hypertension; Kidney Neoplasms; Leucovorin; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2007 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
[Recent advance in chemotherapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Docetaxel; Female; Humans; Irinotecan; Mitoxantrone; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids | 1994 |
CPT-11: the European clinical development.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | 1996 |
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan hydrochloride for treatment of advanced breast cancers].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Topoisomerase I Inhibitors | 2000 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Ovarian Neoplasms; Paclitaxel | 1992 |
48 trial(s) available for camptothecin and Breast Cancer
| Article | Year |
|---|---|
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Middle Aged; Pneumonia; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2022 |
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Triple Negative Breast Neoplasms | 2022 |
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Central Nervous System; Female; Humans; Quality of Life; Receptor, ErbB-2; Trastuzumab | 2023 |
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Progression; Female; Humans; Immunoconjugates; Immunohistochemistry; Receptor, ErbB-2; Trastuzumab | 2022 |
T-DXd: New Standard for HER2-Low Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2022 |
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2022 |
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Cyclin-Dependent Kinase 4; Female; Humans; Immunoconjugates; Irinotecan; Middle Aged; Receptor, ErbB-2; Vinorelbine | 2022 |
Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2022 |
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Consolidation Chemotherapy; Female; Humans; Immunoconjugates; Intention to Treat Analysis; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2020 |
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2020 |
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Cell Adhesion Molecules; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2; Retreatment; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Hormones; Humans; Immunoconjugates; Receptor, ErbB-2; Tumor Microenvironment | 2020 |
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Camptothecin; Drug Approval; Female; Humans; Immunoconjugates; Middle Aged; Receptor, ErbB-2; Trastuzumab; United States | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Topics: Ado-Trastuzumab Emtansine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Follow-Up Studies; Humans; Immunoconjugates; Maximum Tolerated Dose; Middle Aged; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Tissue Distribution; Trastuzumab | 2019 |
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Polymorphism, Genetic; Pyridines; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Europe; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Polyethylene Glycols; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; United States | 2013 |
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids | 2014 |
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Topics: Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Gene Dosage; Genetic Markers; Humans; Irinotecan; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Topoisomerase I Inhibitors; Treatment Outcome | 2015 |
N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cetuximab; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids | 2016 |
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Topics: Adult; Anthracyclines; Apoptosis; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Irinotecan; MCF-7 Cells; Middle Aged; Signal Transduction; Young Adult | 2016 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged | 2008 |
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Salvage Therapy; Topoisomerase Inhibitors; Young Adult | 2013 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Genes, p53; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mutation; Ribosomal Protein S6; Staurosporine; Treatment Outcome | 2013 |
Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Middle Aged; Treatment Outcome | 2003 |
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids | 2004 |
A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer.
Topics: Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Camptothecin; Female; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis | 2004 |
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids | 2005 |
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids | 2005 |
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Disease Progression; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2006 |
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Camptothecin; Cyclin A; Deoxycytidine; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Fluorouracil; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Survival Analysis | 2008 |
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Gene Expression; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
[A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia | 1994 |
Trials of 9-amino-20(S)-camptothecin in Boston.
Topics: Adult; Antineoplastic Agents; Boston; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Neoplasms | 1996 |
[Topotecan--a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15-17 December 1995].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Topotecan | 1996 |
A phase II study of 9-aminocamptothecin in patients with refractory breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Infusions, Intravenous; Middle Aged; Treatment Outcome | 2000 |
[A pilot study of irinotecan hydrochloride for metastatic breast cancer--efficacy as a salvage therapy].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Pilot Projects; Salvage Therapy | 2000 |
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2000 |
[Phase I clinical study of CPT-11. Research group of CPT-11].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms | 1990 |
299 other study(ies) available for camptothecin and Breast Cancer
| Article | Year |
|---|---|
Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents; Benzophenanthridines; Breast Neoplasms; Humans; Leukemia L1210; Leukemia P388; Mice; Molecular Structure; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
Topics: Acylation; Alkylation; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Mice; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Transplantation, Heterologous | 1998 |
Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Catalysis; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Electrophoresis, Agar Gel; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Female; Glioma; Humans; Inhibitory Concentration 50; Lung Neoplasms; Methyl Green; Molecular Structure; Plants, Medicinal; Saccharomyces cerevisiae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triterpenes; Tumor Cells, Cultured | 2001 |
Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Humans; Pyrimidines; Signal Transduction; Urinary Bladder Neoplasms | 2007 |
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2008 |
Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo[3,2-c]quinoline and quinolinoquinoline derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type I; Female; Humans; Indoles; Leukemia; Quinolines; Thiazoles; Topoisomerase I Inhibitors; Triazoles | 2009 |
Antiproliferative activity of withanolides against human breast cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Combinatorial Chemistry Techniques; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Structure-Activity Relationship; Withanolides | 2010 |
Spirocyclic lignans from Guaiacum (Zygophyllaceae) induce apoptosis in human breast cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dominican Republic; Guaiacum; Humans; Lignans; Molecular Structure; Spiro Compounds | 2011 |
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
Topics: Antineoplastic Agents; Aromatase; Breast Neoplasms; Carbolines; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); NF-kappa B; Nitric Oxide; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2011 |
Symmetric dimers of ent-kaurane diterpenoids with cytotoxic activity from Croton tonkinensis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Croton; Dimerization; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Structure-Activity Relationship | 2012 |
Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biotin; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Click Chemistry; Female; Glutathione; Humans; Inhibitory Concentration 50; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Molecular Targeted Therapy; Receptors, Growth Factor; Taxoids | 2014 |
Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines.
Topics: Antineoplastic Agents; Biphenyl Compounds; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Female; Halogenation; HeLa Cells; Humans; Indenes; Pyridines; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Fluorescein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazones; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Bioactive drimane sesquiterpenoids and aromatic glycosides from Cinnamosma fragrans.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Female; Glycosides; Humans; Magnoliopsida; MCF-7 Cells; Models, Molecular; Plants, Medicinal; Polycyclic Sesquiterpenes; Sesquiterpenes | 2017 |
Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzophenanthridines; Breast Neoplasms; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Protein Binding; Structure-Activity Relationship; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2019 |
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred ICR; Microwaves; Molecular Structure; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2019 |
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Peptides; Receptor, ErbB-2 | 2022 |
p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Crk-Associated Substrate Protein; Epiregulin; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Leucovorin; Male; Middle Aged; Molecular Sequence Annotation; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; RNA, Small Interfering; Signal Transduction; Survival Analysis | 2021 |
[Ⅱ. Application for HER2-Positive Breast Cancer(Trastuzumab Deruxtecan)].
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2021 |
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Maytansine; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
[A Case of Superior Vena Cava Syndrome Due to Recurrent Breast Cancer Effectively Treated by Trastuzumab Deruxtecan].
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Middle Aged; Neoplasm Recurrence, Local; Superior Vena Cava Syndrome; Trastuzumab | 2022 |
PDA-coated CPT@MIL-53(Fe)-based theranostic nanoplatform for pH-responsive and MRI-guided chemotherapy.
Topics: Animals; Breast Neoplasms; Camptothecin; Female; Humans; Hydrogen-Ion Concentration; Indoles; Iron; Magnetic Resonance Imaging; Phototherapy; Polymers; Precision Medicine; Theranostic Nanomedicine; Zebrafish | 2022 |
Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Progression-Free Survival; Trastuzumab | 2022 |
Tumor targetable and pH-sensitive polymer nanoparticles for simultaneously improve the Type 2 Diabetes Mellitus and malignant breast cancer.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Mice; Nanoparticles; Polymers; Tumor Microenvironment | 2022 |
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Immunoconjugates; Mutation; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Triple Negative Breast Neoplasms | 2022 |
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Review Literature as Topic; Trastuzumab | 2022 |
Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2022 |
Trastuzumab Deruxtecan for Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Trastuzumab | 2022 |
Trastuzumab Deruxtecan for Breast Cancer. Reply.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Trastuzumab | 2022 |
Trident Molecule with Nanobrush-Nanoparticle-Nanofiber Transition Property Spatially Suppresses Tumor Metastasis.
Topics: Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Hydroxychloroquine; Nanofibers; Nanoparticles; Prodrugs | 2022 |
Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2022 |
Trastuzumab deruxtecan beats trastuzumab emtansine in lowered disease progression, death.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Disease Progression; Female; Humans; Immunoconjugates; Maytansine; Receptor, ErbB-2; Trastuzumab | 2022 |
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2022 |
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |
Antibody-drug Conjugates for Breast Cancer Treatment.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2 | 2022 |
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2022 |
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Camptothecin; Cohort Studies; Female; Humans; Immunoconjugates; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2023 |
Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Trastuzumab | 2022 |
Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Trastuzumab | 2022 |
Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Trastuzumab | 2022 |
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Consensus; Cytotoxins; Female; Humans; Immunoconjugates; Neutropenia; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms; Ventricular Function, Left | 2022 |
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Topics: Brain Neoplasms; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2022 |
Brain Metastasis from HER2-Positive Breast Cancer: An Evolving Landscape.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
T-DXd Keeps Shining in Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Capecitabine; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates | 2023 |
Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates | 2023 |
Novel disulfide bond bridged 7-ethyl-10-hydroxyl camptothecin-undecanoic acid conjugate/human serum albumin nanoparticles for breast cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Disulfides; Female; Humans; Nanoparticles; Prodrugs; Serum Albumin, Human; Xenograft Model Antitumor Assays | 2023 |
In brief: A new breast cancer indication for sacituzumab govitecan (Trodelvy).
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates | 2023 |
In brief: Fam-trastuzumab deruxtecan (Enhertu) for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Glucose-conjugated glutenin nanoparticles for selective targeting and delivery of camptothecin into breast cancer cells.
Topics: Breast Neoplasms; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; MCF-7 Cells; Nanoparticles; Polymers | 2023 |
[New drugs approval: Trastuzumab-deruxtecan - HER2-low metastatic breast cancer].
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
A nanomedicine based on stoichiometric coordination of camptothecin and organoplatinum (II) for synergistic antitumor therapy.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Female; Glutathione; Humans; Hydrogen Peroxide; Mice; Nanomedicine; Polymers | 2023 |
Metastatic
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
T-DXd is effective after T-DM1.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Receptor, ErbB-2; Trastuzumab | 2023 |
Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.
Topics: Biomarkers; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Positron-Emission Tomography; Receptor, ErbB-2; Trastuzumab | 2023 |
HER2-Targeted Therapy Shows Promise across Tumor Types.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Rectal Neoplasms; Trastuzumab | 2023 |
Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2023 |
Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
Optimizing Dosing of Trastuzumab Deruxtecan in
Topics: Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
GSH-activatable camptothecin prodrug-loaded gold nanostars coated with hyaluronic acid for targeted breast cancer therapy
Topics: Breast Neoplasms; Camptothecin; Disulfides; Female; Glutathione; Gold; Humans; Hyaluronic Acid; Hypoxia; Prodrugs; Tumor Microenvironment | 2023 |
Synergistic anti-breast cancer effect of pulsatilla saponin D and camptothecin through interrupting autophagic-lysosomal function and promoting p62-mediated ubiquitinated protein aggregation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Mice; Mice, Nude; RNA-Binding Proteins; Saponins; Tumor Cells, Cultured; Ubiquitin; Ubiquitination; Xenograft Model Antitumor Assays | 2020 |
[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Topics: Animals; Antibodies; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; CTLA-4 Antigen; Disease Models, Animal; Female; Humans; Immunity, Innate; Immunoconjugates; Mice; Receptor, ErbB-2; Trastuzumab | 2019 |
[Synergistic Effect of 2-deoxy-D-glucose Combined with Hydroxycamptothecin on Apoptosis of Breast Cancer Cells].
Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Deoxyglucose; Drug Synergism; Humans; MCF-7 Cells | 2019 |
Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression; Humans; Phosphoric Diester Hydrolases; Topoisomerase I Inhibitors | 2019 |
Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Drug Combinations; Drug Delivery Systems; Female; Humans; Mice; Nanoparticles; Sugar Acids; Trastuzumab; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
Topics: Breast Neoplasms; Camptothecin; Cell Line, Tumor; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2020 |
Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Mice; Mice, Inbred NOD; Nanoparticles; Silicon; Tumor Microenvironment | 2020 |
Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer.
Topics: Breast Neoplasms; Camptothecin; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2020 |
New Drug Approved for HER2-positive Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Infusions, Intravenous; Trastuzumab | 2020 |
A biomimetic nanozyme/camptothecin hybrid system for synergistically enhanced radiotherapy.
Topics: Animals; Biomimetic Materials; Breast Neoplasms; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Manganese Compounds; Mice; Mice, Inbred BALB C; Nanoparticles; Oxides; Particle Size; Porosity; Surface Properties | 2020 |
The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 8; Cell Cycle Checkpoints; Cell Cycle Proteins; Dose-Response Relationship, Drug; Doxorubicin; fas Receptor; Fas-Associated Death Domain Protein; Female; Humans; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Highlights from the 2019 San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Oxazoles; Paclitaxel; Prognosis; Pyridines; Quinazolines; Texas; Trastuzumab | 2020 |
HER2-Targeted Therapies in HER2-Low-Expressing Breast Cancer.
Topics: Breast Neoplasms; Camptothecin; Humans; Immunoconjugates; Trastuzumab | 2020 |
Reply to T.J.A. Dekker.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Humans; Immunoconjugates; Trastuzumab | 2020 |
Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Delivery Systems; Female; Hydrogels; Immunotherapy; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanotubes; Tumor Microenvironment | 2020 |
Antioxidant functions of DHHC3 suppress anti-cancer drug activities.
Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference | 2021 |
Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Hormones; Humans; Immunoconjugates | 2020 |
Dual-Responsive Polyprodrug Nanoparticles with Cascade-Enhanced Magnetic Resonance Signals for Deep-Penetration Drug Release in Tumor Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Contrast Media; Drug Liberation; Drug Screening Assays, Antitumor; Gadolinium DTPA; Magnetic Resonance Imaging; Mice; Molecular Structure; Nanoparticles; Particle Size; Prodrugs; Surface Properties | 2020 |
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.
Topics: Age Factors; Antineoplastic Agents, Immunological; Body Weight; Breast Neoplasms; Camptothecin; Drug Liberation; Female; Humans; Immunoconjugates; Male; Models, Biological; Receptor, ErbB-2; Trastuzumab | 2021 |
[Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Humans; Immunoconjugates; Japan; Receptor, ErbB-2; Trastuzumab | 2021 |
ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Thiazoles | 2021 |
Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa).
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2020 |
A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Differentiation; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred BALB C; Nanomedicine; Nanoparticles; Neoplastic Stem Cells; Rats, Wistar; Tissue Distribution; Tretinoin; Xenograft Model Antitumor Assays | 2021 |
Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Mutation; Trastuzumab | 2021 |
Update on antibody-drug conjugates in breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Maytansine; Trastuzumab | 2021 |
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Topics: Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Trastuzumab | 2021 |
Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
Topics: Adenocarcinoma; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Humans; Immunoconjugates; Kaplan-Meier Estimate; Logistic Models; Multivariate Analysis; Proportional Hazards Models; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
[New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].
Topics: Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Drug Approval; Female; Humans; Immunoconjugates; Multicenter Studies as Topic; Receptor, ErbB-2; Trastuzumab | 2021 |
Sacituzumab Govitecan in Metastatic Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates | 2021 |
Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates | 2021 |
Preparation and anticancer activity evaluation of an amorphous drug nanocomposite by simple heat treatment.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Boric Acids; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Stability; Female; Humans; Lung Neoplasms; Nanocomposites; Solubility | 2017 |
"Bottom-up" Construction of Multi-Polyprodrug-Arm Hyperbranched Amphiphiles for Cancer Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Female; Humans; Mice; Micelles; Polymers; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells.
Topics: Acetylation; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Irinotecan; Matrix Metalloproteinase 9; MCF-7 Cells; Poly(ADP-ribose) Polymerases | 2017 |
Revealing chemical processes and kinetics of drug action within single living cells via plasmonic Raman probes.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Chemical Phenomena; Cisplatin; Female; Fluorouracil; Gold; Humans; Kinetics; MCF-7 Cells; Metal Nanoparticles; Principal Component Analysis; Protein Denaturation; Single-Cell Analysis; Spectrum Analysis, Raman | 2017 |
Chitosan stabilized camptothecin nanoemulsions: Development, evaluation and biodistribution in preclinical breast cancer animal mode.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Chitosan; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Liberation; Drug Stability; Emulsions; Female; Humans; MCF-7 Cells; Mice; Nanoparticles; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; HeLa Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Knockout; Mutation; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Development and evaluation of camptothecin loaded polymer stabilized nanoemulsion: Targeting potential in 4T1-breast tumour xenograft model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Drug Delivery Systems; Drug Liberation; Emulsions; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Poloxamer; Surface Properties; Xenograft Model Antitumor Assays | 2018 |
Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Drug Carriers; Heterografts; Humans; Hyaluronic Acid; Mice; Nanoparticles | 2017 |
Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clusterin; Drug Delivery Systems; Drug Liberation; Endoplasmic Reticulum Chaperone BiP; Female; Gene Knockdown Techniques; Gene Silencing; Gene Transfer Techniques; Humans; Liposomes; MCF-7 Cells; Neoplastic Stem Cells; RNA, Small Interfering | 2019 |
Peptide-Functionalized Phase-Transformation Nanoparticles for Low Intensity Focused Ultrasound-Assisted Tumor Imaging and Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Mice, Nude; Molecular Imaging; Nanoparticles; Optical Imaging; Peptides; Phase Transition; Ultrasonography | 2018 |
FL118, a novel camptothecin analogue, suppressed migration and invasion of human breast cancer cells by inhibiting epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.
Topics: Benzodioxoles; beta Catenin; Breast Neoplasms; Cadherins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D; Epithelial-Mesenchymal Transition; Female; Humans; Indolizines; Inhibitor of Apoptosis Proteins; Neoplasm Invasiveness; Survivin; Vimentin; Wnt Signaling Pathway | 2018 |
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Topics: Animals; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Breast Neoplasms; Camptothecin; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Mice; Programmed Cell Death 1 Receptor; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2018 |
Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Carriers; Drug Compounding; Drug Synergism; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Hyaluronic Acid; MCF-7 Cells; Methotrexate; Mice; Mice, Nude; Nanoparticles; Phosphatidylethanolamines; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Supramolecular Polymer-Based Nanomedicine: High Therapeutic Performance and Negligible Long-Term Immunotoxicity.
Topics: Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Camptothecin; Female; Glutathione; HeLa Cells; Humans; Nanomedicine; Neoplasms; Positron-Emission Tomography; Solubility | 2018 |
Analyte-driven self-assembly of graphene oxide sheets onto hydroxycamptothecin-functionalized upconversion nanoparticles for the determination of type I topoisomerases in cell extracts.
Topics: Biosensing Techniques; Breast Neoplasms; Camptothecin; Cell Extracts; Cell Line, Tumor; DNA Topoisomerases, Type I; Early Detection of Cancer; Electrophoresis, Polyacrylamide Gel; Female; Fluorescence Resonance Energy Transfer; Graphite; Humans; Ligands; Limit of Detection; Nanoparticles; Oxides | 2018 |
Cancer-specific chemotherapeutic strategy based on the vitamin K3 mediated ROS regenerative feedback and visualized drug release in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Coordination Complexes; Drug Delivery Systems; Drug Liberation; Female; Fluorescent Dyes; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Reactive Oxygen Species; Ruthenium; Theranostic Nanomedicine; Vitamin K 3 | 2018 |
Reduced camptothecin sensitivity of estrogen receptor-positive human breast cancer cells following exposure to di(2-ethylhexyl)phthalate (DEHP) is associated with DNA methylation changes.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Proliferation; Diethylhexyl Phthalate; DNA Methylation; Epigenesis, Genetic; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells | 2019 |
Synthesis and Antiproliferative Activities of Conjugates of Paclitaxel and Camptothecin with a Cyclic Cell-Penetrating Peptide.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Esterification; Female; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Paclitaxel; Peptides, Cyclic; Solid-Phase Synthesis Techniques | 2019 |
Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Female; Humans; Measles virus; Oncolytic Virotherapy; Oncolytic Viruses; Tumor Cells, Cultured | 2019 |
A new player in the treatment of HER2-positive tumours.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab | 2019 |
Dual Stable Nanomedicines Prepared by Cisplatin-Crosslinked Camptothecin Prodrug Micelles for Effective Drug Delivery.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cisplatin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Micelles; Nanomedicine; Polyethylene Glycols; Polyglutamic Acid; Prodrugs | 2019 |
Mitochondria-Specific Anticancer Drug Delivery Based on Reduction-Activated Polyprodrug for Enhancing the Therapeutic Effect of Breast Cancer Chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Delayed-Action Preparations; Female; HeLa Cells; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Inbred BALB C; Micelles; Mitochondria; Prodrugs; Reactive Oxygen Species | 2019 |
Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs.
Topics: Antineoplastic Agents; Berberine; Breast Neoplasms; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Breaks; DNA Repair; Down-Regulation; Female; Humans; Hydroxyurea; Neoplasm Proteins; Phthalazines; Piperazines; S Phase; X-ray Repair Cross Complementing Protein 1 | 2019 |
TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Catalytic Domain; Cell Line, Tumor; DNA Fragmentation; DNA Topoisomerases, Type I; Female; Humans; Inhibitory Concentration 50; Mice; Models, Molecular; Molecular Targeted Therapy; Oximes; Quinolines; S Phase Cell Cycle Checkpoints; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
DDX3 regulates DNA damage-induced apoptosis and p53 stabilization.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Caspases; DEAD-box RNA Helicases; DNA Damage; Enzyme Inhibitors; Female; Humans; Immunoblotting; Immunoprecipitation; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
New plant sources of the anti-cancer alkaloid, camptothecine from the Icacinaceae taxa, India.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Magnoliopsida; Ovarian Neoplasms; Phytotherapy; Plant Extracts; Seeds | 2013 |
Targeted delivery of 10-hydroxycamptothecin to human breast cancers by cyclic RGD-modified lipid-polymer hybrid nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Humans; Lipids; Materials Testing; MCF-7 Cells; Molecular Targeted Therapy; Nanocapsules; Oligopeptides; Polymers | 2013 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
Biocatalytic release of an anticancer drug from nucleic-acids-capped mesoporous SiO2 Using DNA or molecular biomarkers as triggering stimuli.
Topics: Antineoplastic Agents; Base Sequence; Biocatalysis; Biomarkers; Breast Neoplasms; Camptothecin; DNA; DNA Primers; Female; Fluorescent Dyes; Humans; Nucleic Acids; Rhodamines; Silicon Dioxide; Spectrometry, Fluorescence | 2013 |
Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Drug Carriers; Drug Delivery Systems; Fatty Acids; Female; Humans; Inhibitory Concentration 50; Lipids; Liposomes; MCF-7 Cells; Nanoparticles; Solubility; Topoisomerase I Inhibitors | 2013 |
Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Nucleus; Cytoplasm; Doxorubicin; Drug Carriers; Female; Humans; Inhibitory Concentration 50; Nanomedicine; Nanoparticles; Nanotubes; Trastuzumab | 2013 |
Etirinotecan pegol: an option for late-stage breast cancer?
Topics: Breast Neoplasms; Camptothecin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Polyethylene Glycols; Topoisomerase I Inhibitors | 2013 |
Down-regulation of tripartite-motif containing 22 expression in breast cancer is associated with a lack of p53-mediated induction.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Camptothecin; DNA Damage; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; MCF-7 Cells; Minor Histocompatibility Antigens; Paclitaxel; Promoter Regions, Genetic; Repressor Proteins; Topoisomerase I Inhibitors; Tripartite Motif Proteins; Tubulin Modulators; Tumor Suppressor Protein p53 | 2013 |
Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Breast Neoplasms; Camptothecin; Carcinoma, Ductal, Breast; Cell Cycle Checkpoints; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; MCF-7 Cells; Middle Aged; Prognosis; Proteasome Endopeptidase Complex; Protein Stability; RNA, Small Interfering; Tumor Suppressor Protein p53; Young Adult | 2013 |
Pharmacokinetics and treatment efficacy of camptothecin nanocrystals on lung metastasis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles; Rats; Survival Rate; Tissue Distribution; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
Topics: Animals; Bone Marrow; Breast Neoplasms; Camptothecin; Cations; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Lipids; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Surface Properties; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines | 2014 |
A novel multifunctional poly(amidoamine) dendrimeric delivery system with superior encapsulation capacity for targeted delivery of the chemotherapy drug 10-hydroxycamptothecin.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chemistry, Pharmaceutical; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Endocytosis; Female; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Integrin alphaVbeta3; Kinetics; Male; MCF-7 Cells; Peptides, Cyclic; Polyamines; Prostatic Neoplasms; Solubility; Surface Properties; Technology, Pharmaceutical | 2014 |
Silencing RBBP6 (Retinoblastoma Binding Protein 6) sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Carrier Proteins; Cell Growth Processes; Combined Modality Therapy; DNA-Binding Proteins; Down-Regulation; Female; Gene Silencing; Humans; MCF-7 Cells; RNA, Small Interfering; Staurosporine; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2014 |
Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Liberation; Female; Humans; Microscopy, Electron, Transmission; Nanostructures; Prodrugs; tau Proteins | 2014 |
Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells.
Topics: Breast Neoplasms; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; HCT116 Cells; Humans; KB Cells; Nanoparticles; Oxidation-Reduction; Polyethylene Glycols; Polymers; Receptor, ErbB-2 | 2014 |
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Topics: Alternative Splicing; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; High-Throughput Screening Assays; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Naphthoquinones; Paclitaxel; Receptor, ErbB-2; Survivin; Tumor Suppressor Protein p53 | 2014 |
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Irinotecan; Metformin; Mice, Nude; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Development and evaluation of magnetic microemulsion: tool for targeted delivery of camptothecin to BALB/c mice-bearing breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; DNA Damage; Drug Delivery Systems; Drug Stability; Emulsions; Female; Humans; Lymphocytes; Magnetic Fields; MCF-7 Cells; Mice; Mice, Inbred BALB C; Particle Size; Polysorbates; Time Factors; Tissue Distribution | 2014 |
Antimetastasis and antitumor efficacy promoted by sequential release of vascular disrupting and chemotherapeutic agents from electrospun fibers.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Camptothecin; Drug Carriers; Drug Liberation; Female; Lactates; Lung Neoplasms; Mice; Mice, Inbred BALB C; Polyethylene Glycols; Stilbenes | 2014 |
Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Breast Neoplasms; Camptothecin; Carboxylic Ester Hydrolases; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mutation; Neoplasm Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2014 |
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Topics: Animals; Antigens, Surface; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Activation; Etoposide; Female; Gefitinib; Humans; Immunophenotyping; MCF-7 Cells; Mice; Neoplastic Stem Cells; Quinazolines; Spheroids, Cellular; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2014 |
Irinotecan as a palliative therapy for metastatic breast cancer patients after previous chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2014 |
BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Tyrosine Phosphatases, Non-Receptor; Protein-Tyrosine Kinases | 2015 |
Selective anticancer activity of hirsutine against HER2‑positive breast cancer cells by inducing DNA damage.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspases; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Irinotecan; MCF-7 Cells; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2 | 2015 |
Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasms; Remission Induction; Topoisomerase I Inhibitors | 2015 |
Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Humans; MCF-7 Cells; Nanoparticles | 2015 |
The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Diffusion; Drug Compounding; Drug Stability; Drug Synergism; Mice; Nanocapsules; Particle Size; Prodrugs; Tocopherols; Treatment Outcome | 2015 |
Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Gene Knockout Techniques; Genomics; Herpesvirus 1, Human; Humans; Irinotecan; Lentivirus; Oncolytic Virotherapy; Phosphorylation; RNA, Small Interfering; Serine-Arginine Splicing Factors; Virus Replication | 2016 |
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Irinotecan; Luminescent Measurements; Mice; Molecular Structure; Permeability; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Topics: Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; HT29 Cells; Humans; MCF-7 Cells; Nitric Oxide; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Up-Regulation | 2015 |
High-content cell death imaging using quantum dot-based TIRF microscopy for the determination of anticancer activity against breast cancer stem cell.
Topics: Breast Neoplasms; Camptothecin; Cell Death; Cisplatin; Humans; Microscopy, Fluorescence; Neoplastic Stem Cells; Quantum Dots; Tumor Cells, Cultured | 2017 |
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Topics: Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; MCF-7 Cells; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Taxoids | 2016 |
Effect of fermentation parameters, elicitors and precursors on camptothecin production from the endophyte Fusarium solani.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Endophytes; Ethanol; Female; Fermentation; Fusarium; Humans; Hydrogen-Ion Concentration; Industrial Microbiology; Temperature | 2016 |
Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Prognosis; Survival Rate; Tumor Cells, Cultured; Werner Syndrome Helicase | 2016 |
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Female; Histones; Humans; Immunoconjugates; Macaca fascicularis; Maytansine; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Receptor, ErbB-2; Topoisomerase I Inhibitors; Trastuzumab | 2016 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2016 |
Pharmacokinetics and Tissue Distribution of Folate-Decorated Human Serum Albumin Loaded With Nano-Hydroxycamptothecin for Tumor Targeting.
Topics: Animals; Breast Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Serum Albumin, Human; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bystander Effect; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Receptor, ErbB-2; Stomach Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2016 |
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression; Humans; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Mice; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
GSK-3 inhibition overcomes chemoresistance in human breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Female; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Irinotecan; Maleimides; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
High-Capacity Drug Carriers from Common Polymer Amphiphiles.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Proliferation; Cell Survival; Drug Carriers; Drug Delivery Systems; Female; Humans; Hydrolysis; Nanoparticles; Particle Size; Polymerization; Polymers; Tumor Cells, Cultured | 2016 |
Bioresponsive polymer coated drug nanorods for breast cancer treatment.
Topics: Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Coated Materials, Biocompatible; Drug Liberation; Female; Humans; Image Processing, Computer-Assisted; Nanotubes; Polyesters; Polymers; Spectroscopy, Fourier Transform Infrared; Trastuzumab | 2017 |
Cisplatin-Stitched Polysaccharide Vesicles for Synergistic Cancer Therapy of Triple Antagonistic Drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Survival; Cisplatin; Dextrans; Doxorubicin; Drug Carriers; Drug Synergism; Female; Humans; Nanoparticles; Polymers | 2017 |
ISG15 as a novel tumor biomarker for drug sensitivity.
Topics: Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cytokines; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Neoplasm; Humans; RNA, Small Interfering; Ubiquitin-Conjugating Enzymes; Ubiquitins | 2008 |
FLEX data, KRAS and ERCC1 testing in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; DNA-Binding Proteins; Drug Delivery Systems; Drug Resistance, Neoplasm; Endonucleases; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Breast Neoplasms; Camptothecin; Diarrhea; Excipients; Gastrointestinal Diseases; Intestinal Mucosa; Male; Neoplasm Proteins; Rats; Rats, Sprague-Dawley | 2008 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Mass Screening; Medical Oncology; Neoplasms; Organoplatinum Compounds; Societies, Medical | 2008 |
Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Fluorescent Antibody Technique; Humans; Interleukins; Lung Neoplasms; Paclitaxel | 2008 |
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
Topics: Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cyclin D1; Drug Synergism; ErbB Receptors; Feedback, Physiological; G1 Phase; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors | 2009 |
Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Drug Synergism; Humans; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Humans; Protein Processing, Post-Translational; Small Ubiquitin-Related Modifier Proteins; Ubiquitin | 2009 |
Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Camptothecin; Cell Cycle Proteins; Checkpoint Kinase 1; Colorectal Neoplasms; DNA Damage; DNA Replication; DNA-Binding Proteins; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Enzyme Inhibitors; Female; HCT116 Cells; Histones; Humans; Protein Kinases; Protein Serine-Threonine Kinases; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Topoisomerase I Inhibitors; Tumor Suppressor Proteins; Up-Regulation | 2009 |
[Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Progression; Humans; Immunotherapy; Irinotecan; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab; Treatment Outcome | 2009 |
Human RIF1 encodes an anti-apoptotic factor required for DNA repair.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Camptothecin; Carcinoma, Ductal, Breast; Cell Differentiation; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; Enzyme Inhibitors; Female; Humans; Immunoenzyme Techniques; Immunoprecipitation; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Repressor Proteins; RNA, Small Interfering; Signal Transduction; Staurosporine; Tumor Cells, Cultured | 2009 |
PKCeta confers protection against apoptosis by inhibiting the pro-apoptotic JNK activity in MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 7; Cell Line, Tumor; Cell Survival; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Isoenzymes; JNK Mitogen-Activated Protein Kinases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase C; Ultraviolet Rays | 2009 |
Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells.
Topics: Apoptosis; bcl-X Protein; Breast Neoplasms; Camptothecin; Caspase 3; Cell Cycle; Cell Line, Tumor; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunoblotting; Membrane Potential, Mitochondrial; RNA, Small Interfering; Valproic Acid | 2009 |
Small cell carcinoma of the breast.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2009 |
Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colony-Forming Units Assay; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; DNA; Drug Synergism; Enzyme Induction; Female; Flavonoids; Humans; Irinotecan; Paclitaxel | 2010 |
Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Time Factors; Tumor Suppressor Protein p53 | 2010 |
The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Female; Humans; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Transfection | 2010 |
[Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance].
Topics: Adult; Aged; Breast Neoplasms; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Multiple; Humans; Irinotecan; Middle Aged; Neutropenia; Recurrence; Salvage Therapy | 2010 |
Hydrophilic mesoporous carbon nanoparticles as carriers for sustained release of hydrophobic anti-cancer drugs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carbon; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Delayed-Action Preparations; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Nanoparticles; Porosity | 2011 |
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Topics: Acridines; Acridones; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Transplantation, Heterologous | 2011 |
Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Diterpenes, Kaurane; Drug Stability; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucosides; HL-60 Cells; Humans; Paclitaxel; Pancreatic Neoplasms; Solvents | 2011 |
[A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Camptothecin; Carcinoma; Fatal Outcome; Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Respiratory Insufficiency; Tomography, X-Ray Computed | 2011 |
Few positives for triple-negative breast cancer.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Chemistry, Pharmaceutical; Disease-Free Survival; Epothilones; Female; Genes, BRCA1; Humans; Irinotecan; Parity; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Treatment Outcome; Tubulin Modulators | 2011 |
Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; DNA Breaks, Double-Stranded; DNA Repair; Enzyme Activation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HeLa Cells; Histones; Humans; Neoplasms; Osteosarcoma; Phosphoprotein Phosphatases; Phosphorylation; RNA, Small Interfering; Substrate Specificity | 2011 |
RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gene Transfer Techniques; Genetic Therapy; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Neoplasm Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase Inhibitors | 2011 |
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan | 2011 |
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA, Neoplasm; Female; Genes, cdc; Genes, erbB-2; Genes, p53; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Receptors, Progesterone; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Irinotecan; Neoplastic Stem Cells; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Receptor, ErbB-2 | 2014 |
Citrus limonin lacks the antichemotherapeutic effect in human models of breast cancer.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line; Cell Line, Tumor; Citrus; Enzyme-Linked Immunosorbent Assay; Female; Humans; Limonins; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2012 |
BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Calcium Channel Blockers; Camptothecin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Irinotecan; KB Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Paclitaxel; Piperidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triterpenes; Verapamil | 2012 |
Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Micelles; Nanoparticles; Prodrugs; Solubility; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
[Importance and practice of UGT1A1 polymorphisms].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Female; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic | 2012 |
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line; Cell Nucleus; Chemokines, CC; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Microscopy, Confocal; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; Cisplatin; Dioxoles; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Isoquinolines; Mice; Mice, Nude; Mitosis; Paclitaxel; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.
Topics: Acrylamides; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Esters; Female; Humans; Lung Neoplasms; Male; Methacrylates; Mice; Mice, Nude; Prostatic Neoplasms; Spectrometry, Fluorescence; Structure-Activity Relationship; Tissue Distribution; Transplantation, Heterologous | 2003 |
Induction of apoptosis in estrogen dependent and independent breast cancer cells by the marine terpenoid dehydrothyrsiferol.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bromodeoxyuridine; Camptothecin; Cell Cycle; Cell Division; Colchicine; DNA; Doxorubicin; Estrogens; Humans; Phosphatidylserines; Pyrans; Tumor Cells, Cultured | 2003 |
The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
Topics: Animals; Breast Neoplasms; Camptothecin; Female; Humans; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase 9; Caspases; Cell Adhesion; Enzyme Activation; Enzyme Precursors; Female; Fibronectins; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotides, Antisense; Poly(ADP-ribose) Polymerases; Protein-Tyrosine Kinases; Sensitivity and Specificity; Topotecan; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1 | 2003 |
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Diarrhea; Intestine, Small; Irinotecan; Male; Neoplasm Transplantation; Rats; Severity of Illness Index | 2003 |
Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; Camptothecin; Caspases; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine; Vincristine; Xenograft Model Antitumor Assays | 2003 |
Stable overexpression of specific segments of the P2P-R protein in human MCF-7 cells promotes camptothecin-induced apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Breast Neoplasms; Camptothecin; Carrier Proteins; Cell Cycle; Enzyme Inhibitors; Humans; Mice; NIH 3T3 Cells; Peptide Fragments; Protein Structure, Tertiary; RNA-Binding Proteins; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
[Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Taxoids | 2003 |
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Etoposide; fas Receptor; Female; Humans; Interleukin-4; Intracellular Signaling Peptides and Proteins; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Up-Regulation | 2004 |
Translocation of Bax and Bid to mitochondria, endoplasmic reticulum and nuclear envelope: possible control points in apoptosis.
Topics: Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Calcium; Camptothecin; Carrier Proteins; Cell Line, Tumor; Cytochromes c; Endoplasmic Reticulum; Female; Humans; Microscopy, Immunoelectron; Mitochondria; Nuclear Envelope; Protein Transport; Proto-Oncogene Proteins c-bcl-2 | 2004 |
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cisplatin; Colonic Neoplasms; Cytarabine; DNA; DNA Adducts; DNA Topoisomerases, Type I; Drug Synergism; Enzyme Inhibitors; Female; Humans; Models, Molecular; Ovarian Neoplasms; Platinum Compounds; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Kinetics of Smac/DIABLO release from mitochondria during apoptosis of MCF-7 breast cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Breast Neoplasms; Calpain; Camptothecin; Carrier Proteins; Cytochromes c; Female; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; Kinetics; Laser Scanning Cytometry; Microscopy, Confocal; Microscopy, Immunoelectron; Mitochondria; Mitochondrial Proteins; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured | 2004 |
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Synthesis and anti-tumor activity of alkenyl camptothecin esters.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Esters; Humans; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasm Transplantation | 2005 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Camptothecin; Carcinoma; Colonic Neoplasms; Coloring Agents; Drug Interactions; Drug Resistance, Neoplasm; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gene Expression Profiling; Humans; Lung Neoplasms; Paclitaxel; Potassium Channels, Voltage-Gated; Tetrazolium Salts; Thiazoles; Transfection; Vincristine | 2005 |
Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Topics: Antibiotics, Antineoplastic; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Clone Cells; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Drug Resistance, Neoplasm; Gamma Rays; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immediate-Early Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Telomerase; Teniposide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
[A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Mastectomy, Segmental; Medroxyprogesterone Acetate; Middle Aged; Pancytopenia; Quality of Life | 2005 |
Enhanced G2-M arrest by nuclear factor-{kappa}B-dependent p21waf1/cip1 induction.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Flow Cytometry; G2 Phase; Humans; Mitosis; NF-kappa B; Nucleic Acid Synthesis Inhibitors; Radiation, Ionizing; RNA Interference; T-Lymphocytes; Time Factors; Tumor Necrosis Factor-alpha | 2005 |
Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Down-Regulation; Female; Gene Expression Profiling; Humans; Hydrogen-Ion Concentration; Tumor Cells, Cultured | 2006 |
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Protein Serine-Threonine Kinases; Quinazolines; rho-Associated Kinases; Thymidylate Synthase; Time Factors; Topoisomerase I Inhibitors | 2005 |
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Butyrates; Camptothecin; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin B; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteins; Survivin; Topoisomerase I Inhibitors; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Cathepsins and BID are involved in the molecular switch between apoptosis and autophagy in breast cancer MCF-7 cells exposed to camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated X Protein; Beclin-1; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Camptothecin; Cathepsin B; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Enzyme Activation; Female; Humans; Kinetics; Laser Scanning Cytometry; Leucine; Membrane Proteins; Microscopy, Confocal; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Mitochondria; Signal Transduction | 2005 |
Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; Tumor Cells, Cultured | 2006 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Topics: Animals; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Cyclodextrins; Disease Models, Animal; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Nanotechnology; Pancreatic Neoplasms; Polymers; Sarcoma, Ewing; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Cell-Free System; Coumarins; Cytochromes c; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Leukemia P388; Lung Neoplasms; Membrane Potentials; Mice; Mitochondria; Mitochondrial Membranes; NIH 3T3 Cells; Rats | 2006 |
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Topics: Animals; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Drug Delivery Systems; Drug Stability; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Nude; Nanostructures; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2006 |
Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Drug Delivery Systems; Drug Evaluation, Preclinical; Female; Hydrogels; Neoplasm Transplantation; Polyethylene Glycols; Rats; Rats, Inbred F344 | 2006 |
[A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Ductal, Breast; Cardiac Tamponade; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intralesional; Irinotecan; Pericardial Effusion; Pericardiocentesis; Pleural Effusion, Malignant; Pleural Neoplasms | 2006 |
Autophagy delays apoptotic death in breast cancer cells following DNA damage.
Topics: Apoptosis; Autophagy; Breast Neoplasms; Camptothecin; Caspases; Cell Line, Tumor; DNA Damage; Gene Expression Regulation, Neoplastic; Humans; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Transcription, Genetic; Tumor Suppressor Protein p53; Up-Regulation | 2007 |
Endonuclease G promotes cell death of non-invasive human breast cancer cells.
Topics: Animals; Apoptosis; Breast; Breast Neoplasms; Camptothecin; Cell Death; Cell Line, Tumor; Cell Movement; DNA Fragmentation; Endodeoxyribonucleases; Etoposide; Humans; Mice; Mice, Knockout; Transfection | 2006 |
Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Biological Transport; Brain Neoplasms; Breast Neoplasms; Camptothecin; Capsules; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dendrimers; Female; Glioblastoma; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Solubility | 2006 |
Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Capsules; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Stability; Humans; Liposomes; Micelles; Nanomedicine; Nanoparticles; Particle Size; Phosphatidylethanolamines; Solubility; Stereoisomerism | 2005 |
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon-gamma; Irinotecan; Mitoxantrone | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Polymerase Chain Reaction; Stomach Neoplasms; Topoisomerase I Inhibitors | 2007 |
Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.
Topics: 3T3 Cells; Animals; Breast Neoplasms; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Mice; Vasoactive Intestinal Peptide | 2007 |
Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Camptothecin; Caspase 8; Cell Line, Tumor; Enzyme Inhibitors; Female; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; Kinetics; Mitochondrial Proteins | 2007 |
[Effects of mitofusin-2 gene on proliferation and chemosensitivity of human breast carcinoma cell line MCF-7].
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA, Complementary; Female; Flow Cytometry; Green Fluorescent Proteins; GTP Phosphohydrolases; Humans; Membrane Proteins; Mitochondrial Proteins; Plasmids; S Phase; Transfection | 2007 |
Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Colorimetry; Drug Screening Assays, Antitumor; Female; Humans; Micelles; Molecular Structure; Poloxamer; Polyethylene Glycols; Solubility; Vitamin E | 2008 |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Primary small cell carcinoma of the breast.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2009 |
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Division; Dimethyl Sulfoxide; Drug Screening Assays, Antitumor; G1 Phase; Humans; Leukemia, Promyelocytic, Acute; Male; Naphthoquinones; Prostatic Neoplasms; Resting Phase, Cell Cycle; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1995 |
Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Breast Neoplasms; Camptothecin; Carcinoma; Cholesterol; Drug Carriers; Drug Evaluation, Preclinical; Humans; Liposomes; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Phosphatidylinositols; Remission Induction; Skin Neoplasms; Sphingomyelins; Topoisomerase I Inhibitors | 1995 |
Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Routes; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
[Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan)].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Soft Tissue Neoplasms | 1994 |
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Synergism; Female; Fibrosarcoma; Humans; Indazoles; Male; Mice; Mice, Inbred C3H; Novobiocin; Topotecan; Tumor Cells, Cultured | 1993 |
Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; In Vitro Techniques; Mice; Mice, Nude; Tumor Cells, Cultured | 1993 |
Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Nucleus; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Female; Humans; Interleukin-1; Irinotecan; Mice; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Protein Biosynthesis; Recombinant Proteins; Transcription, Genetic; Transplantation, Heterologous | 1996 |
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Genetic Variation; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Karyotyping; Kinetics; Nuclear Proteins; Tumor Cells, Cultured | 1996 |
Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Topics: Breast Neoplasms; Camptothecin; Cell Cycle; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Methyl Methanesulfonate; Mutagenesis; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Camptothecin; Carcinoma; Cattle; Cell Division; Cell Nucleus; Cells, Cultured; DNA Topoisomerases, Type I; Endothelium, Vascular; Humans; Liposomes; Mice; Tumor Cells, Cultured | 1996 |
Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Northern; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Female; Fluorouracil; Humans; Insulin-Like Growth Factor I; Laminin; Methotrexate; Microscopy, Electron; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Time Factors; Tumor Cells, Cultured | 1997 |
Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cattle; Cell Cycle; Cell Division; Cells, Cultured; DNA, Neoplasm; Drug Screening Assays, Antitumor; Endothelium, Vascular; Humans; Hydrolysis; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1997 |
Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Female; Humans; Proto-Oncogene Proteins c-bcl-2; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; Humans; Lethal Dose 50; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indenes; Isoquinolines; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Division; DNA; DNA Damage; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1998 |
Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Flow Cytometry; G1 Phase; Genes, p53; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nocodazole; Oncogene Proteins, Viral; Recombinant Fusion Proteins; Repressor Proteins; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 1997 |
Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cytological Techniques; Dimethyl Sulfoxide; DNA Fragmentation; DNA Nucleotidylexotransferase; DNA, Neoplasm; HL-60 Cells; Humans; In Situ Nick-End Labeling; Solvents | 1999 |
Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Caspase Inhibitors; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Neoplasm Proteins; Nuclear Proteins; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Staurosporine; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cholinesterase Inhibitors; Drug Screening Assays, Antitumor; Esters; Female; Glycine; Humans; Infant, Newborn; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured | 1999 |
The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.
Topics: Animals; Base Sequence; Binding Sites; Breast Neoplasms; Camptothecin; Catalysis; Cell Line; DNA; DNA Topoisomerases, Type I; Female; Kinetics; Mitomycin; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Recombinant Proteins; Sequence Deletion; Transcription Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; Doxorubicin; Etoposide; Female; Humans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 1999 |
Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Corn Oil; Drug Synergism; Duodenum; Female; Fish Oils; Gastrointestinal Diseases; Humans; Irinotecan; Lipid Peroxidation; Mice; Mice, Nude; Muscle, Smooth; Thiobarbituric Acid Reactive Substances; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cycloheximide; DNA Replication; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Kinetics; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured | 1999 |
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cattle; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Endothelium, Vascular; G2 Phase; Humans; S Phase; Staurosporine; Tumor Cells, Cultured | 2000 |
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Topics: Adenoviridae; Animals; Apoptosis; Breast Neoplasms; Camptothecin; Cell Nucleus; Colorectal Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Humans; I-kappa B Proteins; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Time Factors; Transgenes; Tumor Cells, Cultured | 2000 |
Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128).
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Cycle; Chromatography, Gel; Chromatography, High Pressure Liquid; Dextrans; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prodrugs; Rats; Rats, Wistar; Time Factors; Tissue Distribution; Topotecan; Tumor Cells, Cultured | 2000 |
Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.
Topics: Aerosols; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Neoplasms, Experimental; Osteosarcoma; Particle Size; Transplantation, Heterologous | 2000 |
Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells.
Topics: Antineoplastic Agents; Base Sequence; Breast Neoplasms; Camptothecin; DNA Damage; Doxorubicin; Estradiol; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Molecular Sequence Data; Protein Isoforms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Messenger; Serum Albumin, Bovine; Tumor Cells, Cultured | 2000 |
Translocation of Bax to mitochondria during apoptosis measured by laser scanning cytometry.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Nucleus; DNA; Female; Flow Cytometry; Humans; Microscopy, Confocal; Microscopy, Fluorescence; Mitochondria; Models, Biological; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents; Breast; Breast Neoplasms; Camptothecin; Cell Cycle; DNA Damage; DNA Repair; DNA Replication; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Neoplasm Proteins; Protein Kinase C; Staurosporine; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Camptothecin analogues with enhanced antitumor activity at acidic pH.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carboxylic Acids; Cell Survival; Cross-Linking Reagents; DNA Damage; Enzyme Inhibitors; Female; Glutathione; Humans; Hydrogen-Ion Concentration; Lactones; Quantitative Structure-Activity Relationship; Spectrophotometry, Ultraviolet; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast; Breast Neoplasms; Camptothecin; Cells, Cultured; Cyclin-Dependent Kinases; Cytoprotection; Doxorubicin; Enzyme Inhibitors; Epithelial Cells; Feasibility Studies; Female; Flow Cytometry; Humans; Interphase; Lymphocytes; Precipitin Tests; Staurosporine; Time Factors; Tumor Cells, Cultured | 2000 |
Structure-activity relationship of alkyl camptothecin esters.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esters; Female; HL-60 Cells; Humans; Mice; Structure-Activity Relationship; U937 Cells; Xenograft Model Antitumor Assays | 2000 |
Pharmacological determinants of 9-aminocamptothecin cytotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Humans; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line; CHO Cells; Colonic Neoplasms; Cricetinae; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Enzymologic; Humans; KB Cells; Peptide Hydrolases; Proteasome Endopeptidase Complex; Ubiquitins | 2001 |
p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner.
Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Camptothecin; Caspases; DNA Damage; DNA-Binding Proteins; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Genes, Reporter; Genes, Tumor Suppressor; Humans; Luciferases; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Recombinant Fusion Proteins; Tetracycline; Transcription, Genetic; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2001 |
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus | 2001 |
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2001 |
Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA, Antisense; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Nuclear Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2001 |
Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cells, Cultured; Dipeptides; Dogs; Drug Design; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Glycoconjugates; Hematopoiesis; Hepatocytes; Humans; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Microscopy, Fluorescence; Rats; Solubility; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
DNA damage is able to induce senescence in tumor cells in vitro and in vivo.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Breast Neoplasms; Camptothecin; Cell Cycle; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Etoposide; Humans; Irinotecan; Neoadjuvant Therapy; Tumor Suppressor Protein p53 | 2002 |
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection | 2002 |
Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Female; Humans; Methotrexate; Mitomycin; RNA, Messenger; Tumor Cells, Cultured | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays | 2002 |
Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma; Colonic Neoplasms; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Leukemia, Myeloid; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Polymerase Chain Reaction; RNA, Neoplasm; Treatment Outcome; Tumor Cells, Cultured | 2002 |
Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Camptothecin; Curcumin; Cyclophosphamide; Cytochrome c Group; Diet; Drug Interactions; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Topics: Acute Disease; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; CHO Cells; Cricetinae; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Flow Cytometry; Leukemia; Membrane Glycoproteins; Quinidine; Topotecan; Tumor Cells, Cultured | 1992 |